A Study of Participants With β-Thalassemia Treated With Betibeglogene Autotemcel
The main aim of this study is to collect real-world longitudinal data on participants with β-thalassemia treated with betibeglogene autotemcel (beti-cel) in the post marketing setting. To assess the long-term safety, including the risk of newly diagnosed malignancies, after treatment with beti-cel and evaluate the long-term effectiveness of treatment with beti-cel.
- EligibilityCriteria: Inclusion Criteria:  Participant must be treated with beti-cel in the post marketing setting at a center in the US that participates in the Registry. Participant must sign an informed consent and/or assent prior to enrollment as required under applicable laws and regulations. Participant must have signed an informed consent and/or assent permitting data to be shared with Center for International Blood and Marrow Transplant Research (CIBMTR). Participant must be followed by a hematologist based in the US.  Exclusion Criteria:  - There are no exclusion criteria for Registry participation. - HealthyVolunteers: No - Gender: All - StdAgeList: Child, Adult, Older Adult - StudyPopulation: Participants with β-thalassemia treated with beti-cel in the post marketing setting at a center in the United States (US) that participates in the Registry. - SamplingMethod: Non-Probability Sample